dual agonist tirzepatide Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology hormone GLP Dual agonist hi-res stock photography

GIP receptors are concentrated in the pancreas, adipose tissue, bone, and the central nervous system

Meta-analyses and large observational papers further suggest that GLP-1RAs are associated with a reduced risk of liver-related clinical events, like progression to cirrhosis

Weekly doses below 2.5 mg have not been tested in a randomized controlled trial

Many patients notice that these symptoms become less disruptive as their body adapts, although the timing and intensity are different for everyone

It is worth noting that the use of SGLT2 inhibitors in type 1 diabetes is off label but occurs in patients with erratic glucose fluctuations or advanced chronic heart failure or chronic kidney disease